Skip to main content

Paradigm Genetics Extends Herbicide Deal with Bayer CropScience

NEW YORK, Nov. 17 (GenomeWeb News) - Paradigm Genetics said today that it has signed a two-year extension of its herbicide discovery collaboration with Bayer CropScience.


This extension, which will take the partnership through Sept. 2006, is the second since the companies began the arrangement, and will include research fees and success fees for assay deliveries. Paradigm also stands to receive royalties from Bayer under the terms of the original deal.


Additional terms were not disclosed.


According to Paradigm, it began in 1998 working to discover novel herbicides that are to be developed and marketed by Bayer CropScience. The term of the inital deal was three years, and included the option for a two-year extension.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.